Clinical trials: Homogentisic Acid
Alkaptonuria
Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria
Nitisinone is a potent inhibitor of the enzyme that catalyzes the formation of homogentisic acid, and should be an even more logical treatment for alkaptonuria than for tyrosinemia, for which it has been approved by the FDA.The…
- Trial name
- NCT01390077
- Testing
- Nitisinone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Diego